Hypofractionated WPPT With HDR Boost

This is a phase II study of ultrahypofractionated whole pelvis proton therapy with brachytherapy boost for patients with high risk or unfavorable intermediate risk prostate with elevated risk of lymph node involvement.

Trial Details

NCT ID
NCT06591819
Phase
PHASE2
Sponsor
Abramson Cancer Center at Penn Medicine
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Hypofractionated Whole Pelvis Proton Therapy with Brachytherapy Boost
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Pathologic evidence of prostate cancer
  • Risk group: high or intermediate risk as defined below
  • High risk: T3a or Gleason Grade Group 4/5 or PSA \>20
  • Unfavorable intermediate risk disease: at least one or more of the following: T2b-T2c, Gleason Grade Group 2/3, PSA 10-20, \>50% of cores positive

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →